Nascent Pharma Holdings's Days Sales Outstanding for the
three
months ended in Sep. 2024 was 14676.04.
Nascent Pharma Holdings's Days Inventory for the
three
months ended in Sep. 2024 was 78.86.
Nascent Pharma Holdings's Days Payable for the
three
months ended in Sep. 2024 was 575.25.
Therefore, Nascent Pharma Holdings's Cash Conversion Cycle (CCC) for the
three
months ended in Sep. 2024 was 14,179.65.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Nascent Pharma Holdings Cash Conversion Cycle Related Terms
Nascent Pharma Holdings Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Nascent Pharma Holdings's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NASC vs ALID, CPMD, PLSH: Cash Conversion Cycle Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Nascent Pharma Holdings's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nascent Pharma Holdings Cash Conversion Cycle vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nascent Pharma Holdings's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Nascent Pharma Holdings's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Nascent Pharma Holdings's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Conversion Cycle of 14,179.65 mean?
Nascent Pharma Holdings (NASC) has a Cash Conversion Cycle of 14,179.65 as of Sep. 2024. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Nascent Pharma Holdings and its competitors.
Is Nascent Pharma Holdings' Cash Conversion Cycle too high?
Nascent Pharma Holdings' current Cash Conversion Cycle is 14,179.65. The Drug Manufacturers industry median Cash Conversion Cycle is 145.72. Nascent Pharma Holdings' value of 14,179.65 is 9631.1% above this industry median. Overall, Nascent Pharma Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Nascent Pharma Holdings' Cash Conversion Cycle compare to ALID and CPMD?
Nascent Pharma Holdings' Cash Conversion Cycle of 14,179.65 can be compared against companies in the Drug Manufacturers industry. The industry median Cash Conversion Cycle is 145.72. Nascent Pharma Holdings' value of 14,179.65 is 9631.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Drug Manufacturers company?
The median Cash Conversion Cycle among Drug Manufacturers companies is 145.72, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nascent Pharma Holdings's current Cash Conversion Cycle of 14,179.65 is 9631.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Nascent Pharma Holdings and its competitors. For the Drug Manufacturers industry, the median Cash Conversion Cycle is 145.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nascent Pharma Holdings's current Cash Conversion Cycle is 14,179.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nascent Pharma Holdings stock overvalued right now?
Nascent Pharma Holdings (NASC) has a current Cash Conversion Cycle of 14,179.65. The current Cash Conversion Cycle is 14,179.65 and 9631.1% above the Drug Manufacturers industry median of 145.72. Nascent Pharma Holdings' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Nascent Pharma Holdings (NASC), the current Cash Conversion Cycle is 14,179.65 as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nascent Pharma Holdings Inc has acquired a Subsidiary engaged in enforcing and commercializing the patents held by Nascent. The acquired patents cover liquid formulations of cannabis. The patents relate to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance for incorporation into a medicament and for use in pharmaceutical formulations, in particular comprising cannabinoids obtained from cannabis. Patented uses include using the liquid formulations to alleviate numerous debilitating conditions, including cancer, irritable bowel syndrome, chronic pain, post-traumatic stress disorder, anxiety, sleep disorders, and opioid dependencies.
12GF Score
Get the complete analysis for NASC
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NASC has been successfully added to your 
